By Swikriti Dandotia
The NHS is set to roll out a major healthcare shift that could impact more than 1.2 million people across England, as weight-loss drugs like Wegovy and Ozempic are being positioned not just for obesity or diabetes, but as a powerful tool to prevent heart attacks and strokes. The move follows new draft guidance from the National Institute for Health and Care Excellence (NICE), which has given the green light for broader use of semaglutide in patients already living with cardiovascular disease.
This is not just another expansion of a popular treatment. It signals a turning point in how weight-loss drugs are being understood. For the first time, people who are overweight but not obese — with a body mass index (BMI) of 27 or above — and who have previously suffered a heart attack, stroke, or circulation problems could soon be eligible for weekly injections on the NHS.
Why the NHS is expanding access now
The decision is rooted in strong clinical evidence. Studies have shown that semaglutide significantly reduces the risk of major cardiovascular events, including heart attack, stroke, and cardiovascular death. One of the most important findings is that this protective effect appears even before significant weight loss occurs. That suggests the drug works directly on the heart and blood vessels, not just by helping patients lose weight.
Previous large-scale research, including work led by University College London and published in The Lancet, found that semaglutide can reduce major cardiac events by around 20%, regardless of how much weight a patient loses. This has shifted the perception of these drugs from lifestyle-focused treatments to essential cardiovascular medicines.
For patients who have already experienced a heart attack or stroke, the risk of another event remains dangerously high. Doctors have long relied on a combination of statins, blood pressure medication, and lifestyle advice to reduce that risk. Now, semaglutide is being added as an extra layer of protection, rather than a replacement for existing treatments.
Who will be eligible for these injections
Under the proposed NICE guidance, the treatment will be offered to people who meet three key conditions. They must have a BMI of 27 or higher, have a history of cardiovascular disease such as a heart attack or stroke, and be considered at high risk of another serious event. This widens access beyond the current focus on obesity and reflects growing confidence in the drug’s broader health benefits.
NHS England estimates that around 1.2 million people could qualify under these criteria. The injections will be provided alongside a reduced-calorie diet and increased physical activity, ensuring that the treatment remains part of a comprehensive care plan rather than a standalone solution.
Importantly, this recommendation is currently in draft form, but NHS officials have indicated that eligible patients could begin accessing the treatment within months. That timeline has already sparked significant interest among patients and healthcare providers.
Why this is being called a ‘gamechanger’
Health leaders have described the move as a major breakthrough. NHS England’s clinical leadership has suggested that this approach could be “life-changing” for people living with high cardiovascular risk. The idea is simple but powerful: instead of waiting for another heart attack or stroke to occur, the system is now aiming to actively prevent it.
Government officials have also backed the shift, calling weight-loss drugs a “gamechanger” in modern medicine. Experts from the British Heart Foundation have emphasized that semaglutide’s benefits go far beyond reducing body weight, positioning it as an important new tool in preventing cardiovascular disease.
For patients, the emotional impact is just as significant. Many people who have survived a heart attack or stroke live with constant anxiety about recurrence. A treatment that can meaningfully lower that risk offers not just medical benefit, but psychological reassurance.
The challenges ahead for the NHS
Despite the optimism, there are real questions about whether the NHS can deliver this programme at scale. Providing access to over a million patients will require careful planning, from prescribing guidelines to supply management and long-term monitoring.
Experts have already raised concerns about capacity. Expanding access to semaglutide means ensuring there are enough trained professionals to assess eligibility, support patients, and track outcomes. There is also the issue of supply, as global demand for drugs like Wegovy and Ozempic has surged in recent years.
Another challenge will be managing expectations. While the headlines may suggest widespread availability, not every patient will qualify. Doctors will need to carefully balance demand with clinical criteria, ensuring that the treatment reaches those who are most at risk.
At the same time, the NHS will need to reinforce that these injections are not a shortcut or a replacement for healthy living. Diet, exercise, and existing medications will remain central to cardiovascular care, with semaglutide acting as an additional safeguard rather than a standalone fix.
Still, the direction of travel is clear. The NHS is moving toward a more proactive model of care, where preventing disease is given as much importance as treating it. The inclusion of semaglutide in cardiovascular prevention reflects a broader shift in medicine, where treatments are increasingly judged by their ability to stop serious events before they happen.
More details from NICE are expected as the guidance is finalized, but the message is already strong. Weight-loss drugs are no longer just about appearance or lifestyle. In the UK’s healthcare system, they are becoming a frontline defense against some of the most dangerous and costly conditions.
For more than a million people at risk, that could mean fewer hospital visits, fewer emergencies, and a much better chance of living longer, healthier lives.
Make Swikblog your go-to source on Google for reliable updates, smart insights, and daily trends.
